Kolexia
Ansquer Catherine Médecine nucléaire
Ansquer Catherine
Médecine nucléaire
Hôpital Hôtel-Dieu Nantes
Nantes, France
123 Activités
1 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs neuroendocrines Hyperparathyroïdie primitive Hyperparathyroïdie Carcinomes Tumeurs de la thyroïde Phéochromocytome Métastase tumorale Tumeurs du pancréas Tumeurs de l'intestin

Collaborateurs

Voir plus
Bodere Francoise
Bodere Francoise
Hôpital Hôtel-Dieu Nantes, Nantes, France
Drui Delphine
Drui Delphine
Hôpital Laennec, Saint-Herblain, France
Mirallie Eric
Mirallie Eric
Hôpital Hôtel-Dieu Nantes, Nantes, France
Taieb David
Taieb David
Hôpital La Timone, Marseille, France

Industries

Voir plus
Advanced Accelerator Applications
17 collaboration(s)
Dernière en 2023
ADVANCED ACCELERATOR APPLICATIONS
3 collaboration(s)
Dernière en 2023
Parexel
3 collaboration(s)
Dernière en 2023
Ipsen
1 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
COMPOSE: A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin
Essai Clinique (ITM Solucin GmbH)   04 mars 2024
OPERANDI-NET: Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort
Essai Clinique (Assistance publique – Hôpitaux de Paris)   13 février 2024
ACTION-1: Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
Essai Clinique (RayzeBio, Inc.)   31 janvier 2024
Performance of Ffluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent disease.
European journal of nuclear medicine and molecular imaging   07 décembre 2023
Place de la TEP-DOTATOC dans le bilan lésionnel initial des néoplasies neuroendocrines bronchiques bien différenciées. Comparaison à la TEP-FDG et à la TDM
39e congrès de la Société Française d'Endocrinologie 2023   01 octobre 2023
A phase I/II study of the safety and efficacy of LuLu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.
European journal of nuclear medicine and molecular imaging   18 septembre 2023
INTERMEDIATE: Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy
Essai Clinique (Centre François-Baclesse)   06 septembre 2023
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs: An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Essai Clinique (Ipsen)   18 juillet 2023
Performance of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Diagnosis of Indeterminate Adrenal Tumors on Conventional Imaging: A French Prospective Multicentric Study
Essai Clinique (Assistance publique - Hôpitaux de Marseille)   05 avril 2023
Métastase surrénalienne d’un mélanome fixant la TEP-FDOPA
Annales d'endocrinologie   01 février 2023